Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Abbott reported Q1 2026 adjusted diluted EPS of $1.15, up 6%, on sales of $11.164B, up 7.8% reported and 3.7% comparable, with strength in Medical Devices and Established Pharmaceuticals offset by weaker Nutrition. The company completed its acquisition of Exact Sciences, adding a new oncology diagnostics growth platform, and raised/affirmed full-year 2026 guidance for comparable sales growth of 6.5% to 7.5% and adjusted EPS of $5.38 to $5.58, including $0.20 of dilution from the deal. Abbott also declared its 409th consecutive quarterly dividend of $0.63 per share.

Analysis

The strategic read-through is not the headline EPS beat; it’s that Abbott just bought itself a higher-quality growth mix while the core portfolio is still compounding. Exact Sciences adds a meaningfully larger, more consumable diagnostic revenue stream that should reduce the market’s discount on Abbott’s multiple, because it shifts the mix away from lower-velocity devices/nutrition toward recurring screening demand. The near-term GAAP drag from integration and amortization is likely to keep reported earnings optically noisy for 2-3 quarters, but that is precisely where the setup improves: investors tend to underwrite the dilution and over-discount the long-dated cross-sell optionality.

The bigger second-order beneficiary is not just ABT, but the broader oncology diagnostics complex. A scaled distribution owner with hospital, physician, and consumer touchpoints can pressure standalone diagnostics players on go-to-market efficiency, and exacts a competitive tax on smaller screening names that rely on external commercialization. On the flip side, Exact Sciences’ installed base and brand should get incremental channel leverage under Abbott, which raises the probability of better retention and lower CAC over the next 12-18 months; that makes the acquisition more accretive to FCF than the current EPS bridge suggests.

The main risk is that the market focuses on the dilution number and misses that the re-rating needs evidence of integration synergies and sustained volume in core labs rather than a one-quarter acquisition bump. Nutrition is still a drag, and if pricing-led recovery lags into Q3, the portfolio can look like a classic “good deal, mediocre quarter” story. The reversal catalyst would be any sign that oncology diagnostics growth decelerates after the initial ownership change or that integration costs stay elevated into year-end, which would cap multiple expansion even if the base business performs.

Contrarian view: consensus may be too quick to treat this as an earnings-accretive M&A story when the more important effect is valuation architecture. If Abbott can prove that oncology screening is a durable, high-visibility annuity with better organic growth than the rest of the portfolio, the stock can de-rate less on device cyclicality and trade closer to a healthcare platform compounder. That rerating is likely a months-long process, not a days-long one.

Key Decisions for Investors

• Long ABT vs. short a basket of slower-growth medtech peers over the next 3-6 months; risk/reward favors ABT if investors start capitalizing Exact Sciences as recurring diagnostics revenue rather than treating it as dilutive M&A.
• Buy ABT on any post-earnings pullback of 3-5% and use a 6-12 month horizon; the setup is asymmetric because reported EPS noise from integration should fade faster than the mix benefit becomes visible.
• Pair trade: long ABT / short a standalone diagnostics name with less scale and weaker commercial distribution over 2-4 quarters; the thesis is margin leverage and channel advantage, not just top-line growth.
• For more tactical expression, sell near-dated downside puts in ABT only on weakness; implied volatility should remain bid around integration uncertainty, but fundamental downside appears limited unless oncology growth underwhelms.
• Avoid chasing EXAS outright here; the acquisition removes the takeover premium and shifts the story from standalone optionality to integration execution, making the risk/reward less attractive over the next 1-2 quarters.